Scott Weston

Partner
Full contact info

I take an engineer’s approach to designing and protecting my clients’ patent portfolios.

Experience

General Catalyst Leads $100 Million Series B Investment in Charm Industrial

June 6, 2023

Cooley advised General Catalyst as lead investor in Charm Industrial’s $100 million Series B financing. Charm Industrial is a developer of carbon removal technology, using plants to capture carbon dioxide from the atmosphere, then converting biomass into a stable, carbon-rich liquid to be pumped deep underground. Harley Brown led the Cooley team advising General Catalyst.

Related contacts

Harley Brown
Partner, Boston
Barry Kuang
Associate, Boston
Scott Weston
Partner, Boston
Mickeala Tu
Associate, Palo Alto

Related Practices & Industries

Baylis Medical Agrees to Sell to Boston Scientific for $1.75 Billion

October 21, 2021

Cooley advised Baylis Medical on its agreement to sell its cardiology business to Boston Scientific for an upfront payment of $1.75 billion. Michael McGrail, Michal Berkner, William Corcoran, Jacqueline Grise and Joshua Friedman led the Cooley team advising Baylis Medical.

Read more

Related contacts

Michael McGrail
Partner, Boston
William Corcoran
Of Counsel, Boston
Jacqueline Grise
Partner, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Thomas Connors
Partner, Boston
Georgina Dietrich
Associate, Brussels
Zack Jenkins
Associate, Boston
Christopher Kimball
Partner, Washington, DC
Calvin Lee
Associate, New York
Richard G.S. Lee
Associate, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Kassity L. Mai
Special Counsel, Reston
Phil Mitchell
Partner, New York
Sarah Oliai
Associate, Washington, DC
Bronwyn L. Roberts
Special Counsel, Boston
Stella Sarma
Special Counsel, Brussels
Jennifer Shanley
Special Counsel, New York
Scott Weston
Partner, Boston

Related Practices & Industries

DBV Technologies Completes Concurrent Public Offerings

November 6, 2014

Cooley advised the underwriters on DBV Technologies' concurrent $106.4 million initial public offering and $28.3 million secondary public offering on Euronext.

DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The company trades on the Nasdaq Global Market under the symbol "DBVT" and on Euronext under the symbol "DBV."

Citigroup Global Markets, Leerink Partners and Bryan, Garnier & Co. acted as joint global coordinators and joint book running managers of the global offering.

Related contacts

Marc Recht
Partner, Boston
Div Gupta
Partner, New York
Brian Leaf
Partner, Reston
Barbara Kosacz
Senior Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Scott Weston
Partner, Boston
Tamim Bazzi
Partner, New York
Danielle Gershowitz
Partner, New York
Phil Mitchell
Partner, New York
Cynthia Kozakiewicz
Special Counsel, Boston

Related Practices & Industries

TriVascular Initial Public Offering

April 23, 2014

San Francisco – Cooley advised the underwriters on TriVascular Technologies' initial public offering. TriVascular is a medical device company that develops and commercializes innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. It now trades on the Nasdaq Global Stock Market under the symbol "TRIV."

JP Morgan Securities and Credit Suisse Securities (USA) acted as joint book-running managers for the offering. Canaccord Genuity and Stifel Nicolaus acted as co-managers.

Year-to-date in 2014, Cooley has advised on 47 completed public offerings, including 24 completed IPOs.

Related contacts

Charlie Kim
Partner, San Diego
Drew Williamson
Partner, San Francisco
David Peinsipp
Partner, San Francisco
Jonie Ing Kondracki
Partner, San Francisco
Scott Talbot
Partner, Reston
Scott Weston
Partner, Boston
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Kevin King
Partner, Washington, DC

Related Practices & Industries

Amedica Initial Public Offering

March 4, 2014

New York – Cooley advised the underwriters on Amedica's initial public offering. Amedica is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. Amedica now trades on the Nasdaq Capital Market under the symbol "AMDA."

JMP Securities acted as the sole book-running manager for the offering. Needham & Co. acted as co-manager for the offering.

In 2013, Cooley's capital markets practice had a record year, advising on 60 public offerings, including 23 IPOs that raised more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 24 completed public offerings, including 13 completed IPOs. Last year, Cooley attorneys also handled more than 120 M&A transactions, with an aggregate deal value of more than $12.4 billion.

Related contacts

Babak (Bo) Yaghmaie
Partner, New York
Charlie Kim
Partner, San Diego
Darren DeStefano
Partner, Reston
Kristin VanderPas
Partner, San Francisco
Mark Ballantyne
Partner, Reston
Dani Nazemian
Special Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Scott Talbot
Partner, Reston
Scott Weston
Partner, Boston

Related Practices & Industries

Rankings & accolades

IAM Patent 1000: Top Patent Lawyer

Legal 500: Top Lawyer for Patent Prosecution

Massachusetts SuperLawyers: Rising Star